#23USNASDAQMid-cap

HALO

Halozyme

$78.60USD

Data as of 2026-07-21

Composite Score69.1Strong

−88

Margin of safety−88%Expensive

Fair value$41.91

Target$83.98

Loss chance51%Neutral

SizeMid cap

SectorHealth Care

Dividend—

TypeCommon stock

Price

Pillar breakdown

0–100 percentile rank against the current universe (sector-relative for Quality / Value / Growth / Profitability)

Health Care median (n=166)

Quality
Profit margins & asset efficiency
91
Exceptional
Health Care median (n=166) 50
Value
Price vs fundamentals
42
Average
Health Care median (n=166) 52
Growth
Revenue & earnings trajectory
91
Exceptional
Health Care median (n=166) 50
Momentum
Recent price strength
54
Average
Health Care median (n=166) 49
Health
Balance sheet & solvency
65
Strong
Health Care median (n=166) 57
Profitability
ROE, ROA, ROIC
81
Exceptional
Health Care median (n=166) 48
Technical
Trend & volatility signals
50
Average
Health Care median (n=166) 56
Risk
Volatility & drawdown profile
66
Strong
Health Care median (n=166) 46

025405570100

Exceptional (70+)Strong (55–70)Average (40–55)Weak (25–40)Poor (<25)

Pillars not shown: Sentiment, ML (Phase 5+).

Fair price check

4 different valuation methods each estimate what HALOshould be worth, then we compare to today's price.

Looks overvalued

Models suggest HALO is trading above fair value

Today's price

$78.60

Median fair price

$41.91

-47% vs today's price

Of 3 methods:1 say fair2 say pricey(1 outlier excluded)

EV/EBITDAFair
thinks it's fairly priced — estimates $83.98, about 7% above today
P/E multiplesOvervalued
thinks it's expensive — estimates $60.35, about 23% below today
DCF (2-stage)Overvalued
thinks it's expensive — estimates $23.47, about 70% below today
P/B multiplesOutlier
estimate looks unreliable — estimates $9.44 — likely unreliable

How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.

Fair price ensemble

Median fair: $41.91
Margin of safety(vs fair value): -87.6%
Max (ex-outliers): $83.98
Tangible BVPS: —

Extreme P/B estimate

Median of all applicable methods (current price $78.60). Per-method estimates + each method’s cheap/fair/pricey read are in the Fair price check above. Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.

Defense layer. Flags mark elevated risk, never confirmed fraud. This model cannot catch every manipulation and decays after publication — weigh it against its stated error rates.

Supporting dataRaw fundamentals & data-quality provenance behind the scores above

Raw fundamentals (SEC EDGAR)

Metric	Value
Market cap	$9.32B
Revenue (TTM)	$1.51B
Net income (TTM)	$348.84M
Operating cash flow (TTM)	$677.41M
CapEx (TTM)	$9.76M
Free cash flow (TTM)CFO − CapEx	$667.65M
Total assets	$2.67B
Total liabilities	$2.45B
Stockholders' equity	$219.64M
Cash & equivalents	$309.75M
Shares outstanding	118.61M
EPS (basic)	$2.94
EPS (diluted)	$2.94
P/E ratio (TTM)	26.73

TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).

Data quality

Latest filed date: 2026-05-11
Latest period end: 2026-04-30
Filing lag: 71 days
Missing metrics: 2(gross_profit, dividends_paid)